NO20012721L - Plasmidopprettholdelsessystem for antigenavgivelse - Google Patents

Plasmidopprettholdelsessystem for antigenavgivelse

Info

Publication number
NO20012721L
NO20012721L NO20012721A NO20012721A NO20012721L NO 20012721 L NO20012721 L NO 20012721L NO 20012721 A NO20012721 A NO 20012721A NO 20012721 A NO20012721 A NO 20012721A NO 20012721 L NO20012721 L NO 20012721L
Authority
NO
Norway
Prior art keywords
plasmid
expression
maintenance system
expression plasmids
retention system
Prior art date
Application number
NO20012721A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012721D0 (no
Inventor
James E Galen
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/204,117 external-priority patent/US6413768B1/en
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of NO20012721D0 publication Critical patent/NO20012721D0/no
Publication of NO20012721L publication Critical patent/NO20012721L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20012721A 1998-12-02 2001-06-01 Plasmidopprettholdelsessystem for antigenavgivelse NO20012721L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/204,117 US6413768B1 (en) 1998-12-02 1998-12-02 Expression plasmids
US15873899P 1999-10-12 1999-10-12
PCT/US1999/028499 WO2000032047A1 (en) 1998-12-02 1999-12-02 Plasmid maintenance system for antigen delivery

Publications (2)

Publication Number Publication Date
NO20012721D0 NO20012721D0 (no) 2001-06-01
NO20012721L true NO20012721L (no) 2001-07-31

Family

ID=26855335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012721A NO20012721L (no) 1998-12-02 2001-06-01 Plasmidopprettholdelsessystem for antigenavgivelse

Country Status (15)

Country Link
US (6) US6703233B1 (de)
EP (1) EP1135025B1 (de)
JP (1) JP2003506007A (de)
AT (1) ATE360366T1 (de)
AU (1) AU776562B2 (de)
CA (1) CA2352457A1 (de)
CZ (1) CZ20011538A3 (de)
DE (1) DE69935927T2 (de)
DK (1) DK1135025T3 (de)
ES (1) ES2286905T3 (de)
HU (1) HUP0104609A2 (de)
NO (1) NO20012721L (de)
NZ (2) NZ529507A (de)
PL (1) PL349041A1 (de)
WO (1) WO2000032047A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076130B2 (en) * 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
EP1135025B1 (de) * 1998-12-02 2007-04-25 University of Maryland, Baltimore Plasmidstabilisierungssystem für die verabreichung von antigenen
DK1154791T3 (da) * 1999-02-22 2008-06-16 Health Prot Agency Neisseria-vaccinesammensætninger og fremgangsmåder
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
AU777298B2 (en) * 1999-09-10 2004-10-07 Secretary Of State For Defence, The Recombinant microorganisms
GB0024203D0 (en) * 2000-10-03 2000-11-15 Peptide Therapeutics Ltd Stabilisation of plasmid inheritance in bacteria
EP1917975A1 (de) 2001-11-30 2008-05-07 University of Maryland, Baltimore Neuartige Proteine in Enteroaggregativen Escherichia Coli (EAEC) zur Diagnose und Therapie von EAEC-Infektionen
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
GB0327056D0 (en) * 2003-11-20 2003-12-24 Cobra Biolog Ltd Plasmid maintenance
AU2004314710A1 (en) * 2003-12-12 2005-08-11 Conjugon, Inc. Systems for tightly regulated gene expression
US8137930B2 (en) 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
AU2006308966A1 (en) * 2005-10-28 2007-05-10 University Of Maryland, Baltimore Attenuated salmonella enterica Serovar Paratyphi A and uses thereof
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009011940A2 (en) * 2007-04-06 2009-01-22 University Of Maryland, Baltimore Microcin h47 plasmid selection system
US20100317084A1 (en) * 2007-05-10 2010-12-16 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
JP2010533000A (ja) * 2007-07-12 2010-10-21 ユニヴァーシティ オブ メディシン アンド デンティストリ オブ ニュージャーシィ 抗毒素不安定化技術
US8465755B2 (en) * 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
JP5210675B2 (ja) * 2008-03-19 2013-06-12 株式会社東芝 不揮発性半導体記憶装置及びその製造方法
WO2009149083A2 (en) 2008-06-03 2009-12-10 University Of Maryland, Baltimore Non-hemolytic clya for excretion of proteins
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
WO2011091291A1 (en) 2010-01-22 2011-07-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
WO2012069551A1 (en) 2010-11-23 2012-05-31 Oslo Universitetssykehus Hf Dinq-srna type i toxin-antitoxin system for plasmid maintenance
WO2012087483A1 (en) * 2010-11-24 2012-06-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium comprising a toxin/antitoxin system
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
EP2906682B1 (de) * 2012-10-15 2025-06-11 University of Maryland, Baltimore Chromosomal integrierte fremdantigene exprimierende bakterielle lebendvektorimpfstoffe
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
EP3105311A1 (de) 2014-02-10 2016-12-21 Univercells NV System, vorrichtung und verfahren zur herstellung von biomolekülen
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
MY202505A (en) 2017-11-03 2024-05-01 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
CN109321591B (zh) * 2018-10-22 2021-07-13 上海海洋大学 一种重组质粒及其构建方法
JP2023516420A (ja) * 2020-03-05 2023-04-19 ユニヴァーシティー オブ メリーランド バルチモア がんタンパク質抗原を発現するように操作された生チフス菌ベクターおよびその使用方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US5643771A (en) 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
DK410783D0 (da) * 1982-09-16 1983-09-09 Benzon A Salfred Fremgangsmade til stabilisering af plasmider
US4764370A (en) * 1984-09-12 1988-08-16 Scripps Clinic And Research Foundation Vaccine utilizing an avirulent strain of Salmonella typhimurium
DK275685D0 (da) * 1985-06-18 1985-06-18 Benzon As Alfred Stabilisering af biologiske systemer
AU7232087A (en) 1986-03-26 1987-10-20 Genexpress Aps Biological containment
AU637969B2 (en) * 1987-10-07 1993-06-17 Washington University A method of maintaining a desired recombinant gene in a genetic population of cells
US5811105A (en) 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5695983A (en) 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
US5459072A (en) 1992-02-25 1995-10-17 Regents Of The University Of Minnesota Food-grade integration vectors for industrial bacterial strains
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
US5824538A (en) * 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5922583A (en) * 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
EP1135025B1 (de) * 1998-12-02 2007-04-25 University of Maryland, Baltimore Plasmidstabilisierungssystem für die verabreichung von antigenen

Also Published As

Publication number Publication date
WO2000032047A1 (en) 2000-06-08
HUP0104609A2 (hu) 2002-03-28
US20060030047A1 (en) 2006-02-09
JP2003506007A (ja) 2003-02-18
CA2352457A1 (en) 2000-06-08
US6969513B2 (en) 2005-11-29
ATE360366T1 (de) 2007-05-15
AU776562B2 (en) 2004-09-16
DE69935927T2 (de) 2008-01-10
US6703233B1 (en) 2004-03-09
EP1135025A1 (de) 2001-09-26
DE69935927D1 (de) 2007-06-06
US7141408B2 (en) 2006-11-28
NZ529507A (en) 2005-05-27
CZ20011538A3 (cs) 2001-11-14
US20040161420A1 (en) 2004-08-19
US7125720B2 (en) 2006-10-24
AU2036400A (en) 2000-06-19
PL349041A1 (en) 2002-07-01
DK1135025T3 (da) 2007-08-13
EP1135025A4 (de) 2004-11-17
US20060029616A1 (en) 2006-02-09
NZ511449A (en) 2004-05-28
US7138112B2 (en) 2006-11-21
US20050003539A1 (en) 2005-01-06
ES2286905T3 (es) 2007-12-01
NO20012721D0 (no) 2001-06-01
US20060030048A1 (en) 2006-02-09
US6977176B2 (en) 2005-12-20
EP1135025B1 (de) 2007-04-25
WO2000032047A9 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
NO20012721D0 (no) Plasmidopprettelsessystem for antigenavlevering
WO2002021316A3 (en) Mechanism and method for continuous operation of a rule server
DE69633581D1 (de) Alphavirus rna replikon-systeme
NO902995L (no) Stabilisert fgf sammensetning samt fremstilling derav.
IL122614A0 (en) Packaging systems for human recombinant adenovirus to be used in gene therapy
CA2203149A1 (fr) Ensemble de rouleau pour le transport d'articles a temperature elevee
PT783314E (pt) Composicoes para o tratamento de irds e de ards, que contem pelo menos um glucocorticosteroide em combinacao com um agente tensioactivo pulmonar
PT84155A (en) Method of modifying plant viruses or their effects
NO951879L (no) Polymersammensetning med forbedret termisk oksiderende stabilitet og fremgangsmåte til dens fremstilling
HUP9901958A2 (hu) Sertés reproduktív és respirációs szindróma vakcina
NO952138L (no) Cefiximpreparat
NO178028C (no) Fremgangsmåte ved fremstilling av 3-(L-pyroglutamyl)-L-tiazolidin-4-karboksylsyre samt derivater derav
AU630099B2 (en) Non-reverting rna viruses
HAN et al. Effect of YAG laser iridotomy on IOP in chronic angle-closure glaucoma
SU918453A1 (ru) Способ определени величины нечувствительности системы регулировани турбины
DK1029063T3 (da) Ikke-RCR leuconostoc-plasmid, der kan overföres til mælkesyrebakterier, anvendelse som klonings- og ekspressionsredskab
DK0441112T3 (da) Skrueprop
SONG et al. Hemagglutinin A of Porphyromonas gingivalis function as adhesion and invasion in human gingival epithelial cells
JPS5436501A (en) Internal pressure maintaining system for internal pressure type exploson- proof electric machine
東孝博 The Renormalized Energy-momentum Tensor in Some Robertson-Walker Universe
Ramsey Turbo Lightning and Strike.
Macherauch et al. Failure Considerations and Practical Dimensioning Rules for Components Under Quasi-static Loading
HONMA Idiopathic calcinosis of the scrotum
早川尚男 6a-R-13 Dynamics of the Ising Model with Long-Range Exchange II
任憶安 Studies on the Market for Imported American Timber in Taiwan

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application